We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

110 hedge funds and large institutions have $136M invested in Ventyx Biosciences in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 39 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

253% more call options, than puts

Call options by funds: $522K | Put options by funds: $148K

43% more capital invested

Capital invested by funds: $95.1M → $136M (+$41.3M)

0.94% less ownership

Funds ownership: 62.43%61.5% (-0.94%)

4% less funds holding

Funds holding: 114110 (-4)

17% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 23

21% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 39

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
110
Holders Change
-4
Holders Change %
-3.51%
% of All Funds
1.44%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
19
Increased
31
Reduced
39
Closed
23
Calls
$522K
Puts
$148K
Net Calls
+$374K
Net Calls Change
+$113K
Name Holding Trade Value Shares
Change
Change in
Stake
BFM
26
Boothbay Fund Management
New York
$1.35M +$403K +152,114 +54%
Macquarie Group
27
Macquarie Group
Australia
$1.34M
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$1.31M +$522K +197,004 +88%
Goldman Sachs
29
Goldman Sachs
New York
$1.27M -$460K -173,453 -30%
Charles Schwab
30
Charles Schwab
California
$1.24M +$134K +50,678 +15%
Jane Street
31
Jane Street
New York
$1.2M -$41K -15,493 -4%
TCM
32
TCG Crossover Management
California
$983K
Two Sigma Advisers
33
Two Sigma Advisers
New York
$982K +$379K +143,200 +83%
State Street
34
State Street
Massachusetts
$895K +$3.44K +1,299 +0.5%
Morgan Stanley
35
Morgan Stanley
New York
$758K -$735K -277,261 -53%
GCP
36
GSA Capital Partners
United Kingdom
$753K +$642K +242,229 New
Renaissance Technologies
37
Renaissance Technologies
New York
$731K +$434K +163,700 +230%
BCM
38
Bridgeway Capital Management
Texas
$726K +$477K +180,000 +336%
MAM
39
Monaco Asset Management
Monaco
$702K -$1.42M -536,288 -70%
SSA
40
Schonfeld Strategic Advisors
New York
$666K +$567K +214,189 New
XT
41
XTX Topco
Cayman Islands
$629K +$108K +40,771 +25%
Walleye Capital
42
Walleye Capital
New York
$577K -$627K -236,629 -56%
AQR Capital Management
43
AQR Capital Management
Connecticut
$571K -$1.45M -546,412 -75%
SPS
44
Susquehanna Portfolio Strategies
Pennsylvania
$525K +$24.6K +9,284 +6%
SC
45
Stempoint Capital
New York
$521K +$444K +167,470 New
GCM
46
Graham Capital Management
Connecticut
$495K +$304K +114,691 +258%
CIBC World Market
47
CIBC World Market
Ontario, Canada
$483K -$264K -99,750 -39%
PFS
48
Prospera Financial Services
Texas
$466K +$1.59K +600 +0.4%
Qube Research & Technologies (QRT)
49
Qube Research & Technologies (QRT)
United Kingdom
$456K +$388K +146,605 New
CFG
50
Citizens Financial Group
Rhode Island
$442K +$377K +142,193 New

VTYX Hedge Fund Activity: Q3 2025 in Review

110 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2025, worth a combined $136M — up 43% from $95.1M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of VTYX and 19 opened new positions — a net loss of 4 holders — while 39 trimmed existing stakes and 31 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $2.71M. The largest seller was Point72 Asset Management, cutting an estimated $7.11M.

  • 110 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2025, down from 114 in Q2 2025.
  • Funds reported $136M of Ventyx Biosciences stock for Q3 2025, up 43% quarter-over-quarter.
  • 19 funds opened new Ventyx Biosciences positions in Q3 2025 and 23 closed out, a net change of -4 holders.
  • The largest Ventyx Biosciences buyer in Q3 2025 was Baker Bros. Advisors, an estimated $2.71M added.
  • The largest Ventyx Biosciences seller in Q3 2025 was Point72 Asset Management, an estimated $7.11M sold.

Based on aggregated 13F filings for Q3 2025.